DEPOMED,INC. (NASDAQ:DEPO) Files An 8-K Other Events

ME Staff 8-k
-
0

DEPOMED,INC. (NASDAQ:DEPO) Files An 8-K Other Events
Item 8.01 Other Events.

On July9, 2018, Depomed,Inc. (the “Company”) announced that it is currently engaged in settlement discussions with Purdue Pharma L.P. (“Purdue”) in connection with ongoing patent infringement litigation between the Company and Purdue. As the order issued by the Court today indicates, the caseand any pending motions have been administratively terminated,pending the outcome of such discussions. The Court’s order does not constitute a dismissal with prejudice of the case under the Federal Rulesof Civil Procedure. As further indicated in the Court’s order, if settlement cannot be consummated, either party may request that the action be reopened.


About DEPOMED,INC. (NASDAQ:DEPO)

Depomed, Inc. is a specialty pharmaceutical company focused on pain and other central nervous system (CNS) conditions. The Company’s products include NUCYNTA ER (tapentadol extended release tablets), which is a product for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and for which alternate treatment options are inadequate; NUCYNTA (tapentadol), which is an immediate release version of tapentadol for the management of moderate to severe acute pain in adults; Gralise, which is a once-daily product for the management of postherpetic neuralgia; CAMBIA, which is a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Zipsor, which is a NSAID for the treatment of mild to moderate acute pain, and Lazanda nasal spray, which is used for the management of break through pain in cancer patients.